Semaglutide is a long-acting analog of GLP-1 (glucagon-like peptide 1), designed to resist enzymatic degradation and bind reversibly to serum albumin. It is one of the most studied compounds in metabolic pharmacology of the last decade.
Molecular design
Compared with native GLP-1 (half-life ~2 minutes), semaglutide incorporates three key modifications:
- Ala8 → Aib substitution (α-aminoisobutyric acid). It blocks cleavage by DPP-4 (dipeptidyl peptidase 4), the main enzyme that degrades native GLP-1.
- Lys34 → Arg substitution. It avoids interference with the next step.
- Acilación en Lys26 con ácido graso C18 (ácido octadecanoico) vía espaciador γ-Glu-2xOEG. Este “ancla lipídica” permite que la molécula se una reversiblemente a albúmina, multiplicando la vida media a ~165 horas.
Mechanism of action
- Pancreas: stimulates glucose-dependent insulin secretion in beta cells; suppresses glucagon secretion in alpha cells.
- Brain: it acts on the arcuate nucleus of the hypothalamus (POMC/CART pathway), suppressing appetite and increasing satiety.
- Gastrointestinal tract: slows gastric emptying, contributing to prolonged postprandial satiety.
- Cardiovascular system: anti-inflammatory and vascular remodeling effects documented in cohorts at CV risk.
Common preclinical models
Research with semaglutide in animal models usually uses:
- DIO (diet-induced obesity) mice — the most common model for evaluating weight loss.
- db/db mice (leptin receptor-deficient) — a type 2 diabetes model.
- Zucker fa/fa rats — genetic obesity.
- Non-human primate models for translational pharmacokinetics.
Usual endpoints in preclinical studies
- Body weight and composition (DXA or MRI).
- Basal blood glucose and glucose tolerance test (GTT).
- HbA1c (in studies lasting >8 weeks).
- Marcadores inflamatorios (TNF-α, IL-6, CRP).
- Liver histology and triglyceride content (NAFLD/NASH models).
Differences between subcutaneous and oral semaglutide
Although there is an oral formulation (with an absorption-enhancing agent), most research is done with the subcutaneous formulation for reasons of bioavailability and reproducibility. Reported oral bioavailability is on the order of 0.4–1%.
Considerations for laboratory research
- Molar dose, not milligrams, for comparisons with other GLP-1 agonists.
- Vehicle: PBS pH 7.4 is standard; some protocols use 30 mM acetate.
- Frequency: in rodents, daily doses or every 3 days, given the shorter half-life in these species.
The semaglutide in the NeoPeptidos catalog is a synthetic product of ≥99% HPLC purity for laboratory research use only. It is not an approved pharmaceutical product and must not be used in humans outside authorized clinical protocols.
🔬 Updated on March 12, 2026 · Reviewed by the NeoPeptidos team · Content for research purposes (RUO).